Drug: Blinatumomab (Blincyto, Amgen)
Status: Approved to treat pediatric patients with Philadelphia chromosome–negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)
Significant Data:
- The approval is based on results from the Phase I/II '205, an open-label, multicenter, single-arm trial, which evaluated the efficacy and safety of Blincyto in 93 patients with relapsed or refractory B-cell precursor ALL
- Treatment in this study has been completed and subjects